{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:32:21Z","timestamp":1767695541527,"version":"3.48.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.prro.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:59:04Z","timestamp":1749470344000},"page":"e28-e37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinician- and Patient-Reported Outcomes of Stereotactic Ablative Radiation Therapy for High-Risk Prostate Cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Helena B.Z.","family":"Logar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-0493","authenticated-orcid":false,"given":"Angel","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidio","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Ciervide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen-Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariola","family":"Garcia-Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyre","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Fernandez-Leton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.05.007_bib0001","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2025.05.007_bib0002","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.05.007_bib0003","first-page":"583","article-title":"NCCN guidelines updates: Management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.prro.2025.05.007_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","article-title":"What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation","volume":"115","author":"Zaorsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0006","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"16","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0007","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0008","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial","volume":"81","author":"Yeoh","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0009","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.radonc.2017.04.003","article-title":"Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy","volume":"123","author":"Raziee","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0011","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JU.0000000000000071","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO and AUA evidence-based guideline","volume":"201","author":"Morgan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2025.05.007_bib0012","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.prro.2017.06.002","article-title":"Extreme hypofractionation for high-risk prostate cancer: Dosimetric correlations with rectal bleeding","volume":"7","author":"Bauman","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0013","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","article-title":"Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high risk and node-positive prostate cancer","volume":"30","author":"Murthy","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2025.05.007_bib0014","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): Early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.adro.2018.12.001","article-title":"Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer","volume":"4","author":"Pinitpatcharalert","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2019.12.044","article-title":"Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: A toxicity and quality-of-life comparison of two prospective trials","volume":"107","author":"Alayed","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: Analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0018","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clon.2020.10.019","article-title":"Safety and efficacy of ultra-hypofractionation in node-positive prostate cancer","volume":"33","author":"Telkhade","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2025.05.007_bib0019","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3390\/cancers14143484","article-title":"A prospective study of stereotactic body radiotherapy (SBRT) with concomitant whole-pelvic radiotherapy (WPRT) for high-risk localized prostate cancer patients using 1.5 Tesla magnetic resonance guidance: The preliminary clinical outcome","volume":"14","author":"Poon","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2025.05.007_bib0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijrobp.2021.10.137","article-title":"SABR for high-risk prostate cancer: A prospective multilevel MRI-based dose escalation trial","volume":"113","author":"Hannan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0021","article-title":"A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.prro.2025.05.007_bib0022","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/j.ijrobp.2023.06.2500","article-title":"Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high risk and very high-risk prostate cancer on 1.5-1.5 MR linac: The estimated delivered dose and early toxicity results","volume":"117","author":"Gao","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0023","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.prro.2023.08.006","article-title":"Long-term outcomes following fairly brief androgen suppression and stereotactic radiation therapy in high-risk prostate cancer: Update from the FASTR\/FASTR-2 trials","volume":"14","author":"Tang","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0024","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","article-title":"Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: Primary outcomes of the SPARC phase 2 trial","volume":"120","author":"Yasar","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0026","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.ijrobp.2024.07.224","article-title":"Magnetic resonance imaging-guided vs. computed tomography-guided stereotactic body radiotherapy for prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"120","author":"Kishan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0027","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ijrobp.2023.09.053","article-title":"Safety of ultrahypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: Systematic review and meta-analysis","volume":"118","author":"Mohamad","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0028","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canrad.2023.07.014","article-title":"Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes","volume":"28","author":"Faria","year":"2024","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.prro.2025.05.007_bib0029","article-title":"Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials","volume":"49","author":"Glicksman","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818789633","article-title":"Stereotactic body radiotherapy for primary prostate cancer","volume":"17","author":"Kothari","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.prro.2025.05.007_bib0031","article-title":"Fiducial marker guided prostate radiotherapy: A review","volume":"89","author":"O\u2019Neill","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2025.05.007_bib0032","first-page":"3095","article-title":"Analysis of prostate bed motion using an endorectal balloon and cone beam computed tomography during postprostatectomy radiotherapy","volume":"9","author":"Joo","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.prro.2025.05.007_bib0033","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2010.04.016","article-title":"Is there a role for endorectal balloons in prostate radiotherapy? A systematic review","volume":"95","author":"Smeenk","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0034","first-page":"227","article-title":"Emerging evidence for the role of an endorectal balloon in prostate radiation therapy","volume":"1","author":"Both","year":"2012","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.prro.2025.05.007_bib0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2018.11.011","article-title":"SABR in high-risk prostate cancer: Outcomes from 2 prospective clinical trials with and without elective nodal irradiation","volume":"104","author":"Alayed","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0036","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PPO.0000000000000425","article-title":"Stereotactic ablative body radiotherapy for intermediate- or high-risk prostate cancer","volume":"26","author":"Loblaw","year":"2020","journal-title":"Cancer J"},{"key":"10.1016\/j.prro.2025.05.007_bib0037","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1748-717X-9-52","article-title":"Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer","volume":"9","author":"Bhattasali","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0038","article-title":"Impact of age on patient-reported outcomes following stereotactic body radiation therapy for prostate cancer","volume":"13","author":"Pepin","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.prro.2025.05.007_bib0039","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13014-022-02061-y","article-title":"Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: A longitudinal study","volume":"17","author":"Yamashita","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0040","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","article-title":"Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: Results of the PACE-A randomised trial","volume":"86","author":"van As","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2025.05.007_bib0041","article-title":"Stereotactic magnetic resonance\u2013guided daily adaptive radiation therapy for localized prostate cancer: Acute and late patient-reported toxicity outcomes","volume":"9","author":"Nugent","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0042","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.prro.2022.09.007","article-title":"Magnetic resonance-guided adaptive radiation therapy for prostate cancer: The first results from the MOMENTUM study\u2014An international registry for the evidence-based introduction of magnetic resonance-guided adaptive radiation therapy","volume":"13","author":"Teunissen","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0043","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0044","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.3390\/cancers16223832","article-title":"Do patient-reported outcome measures (PROMs) used within radiotherapy clinical trials reflect the impact of treatment?","volume":"16","author":"Fairweather","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2025.05.007_bib0045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semradonc.2024.07.001","article-title":"Prioritizing patient-centered care in a world of increasingly advanced technologies and disconnected care","volume":"34","author":"Marion","year":"2024","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0046","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2015.07.016","article-title":"Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy","volume":"116","author":"Evans","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.007_bib0047","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2016.11.007","article-title":"Clinical investigation exploring value from the Patient\u2019s perspective between modern radiation therapy modalities for localized prostate cancer radiation oncology","volume":"97","author":"Shaverdian","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.007_bib0048","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:31:04Z","timestamp":1767695464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1879850025001511"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.007","relation":{},"ISSN":["1879-8500"],"issn-type":[{"type":"print","value":"1879-8500"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinician- and Patient-Reported Outcomes of Stereotactic Ablative Radiation Therapy for High-Risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}